FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)



Modulated lysine variant species compositions and methods for producing and using the same
04/23/15 - 20150110775 - The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in...

Antibodies that recognize iapp
04/23/15 - 20150110776 - The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome,...

Antibodies that recognize iapp
04/23/15 - 20150110777 - The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome,...

Compositions comprising mg53 and methods for the treatment and prevention of airway injury
04/23/15 - 20150110778 - Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof....

Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
04/23/15 - 20150110779 - The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a cancer patient will experience a gastrointestinal immune-related adverse event (GI-irAE) after administration of a pharmaceutically acceptable amount of an activator of the immune system....

Treatment of brain cancer
04/23/15 - 20150110780 - Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein....

Compositions and methods related to the prevention and treatment of rabies infection
04/23/15 - 20150110781 - The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection....

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
04/23/15 - 20150110782 - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the...

Antagonist anti-cd40 antibody pharmaceutical compositions
04/23/15 - 20150110783 - Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and...

Therapeutic combinations and methods including irm compounds
04/23/15 - 20150110784 - The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component....

Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
04/23/15 - 20150110785 - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders....

Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence
04/16/15 - 20150104442 - Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a...

Anti-erbb2 antibody variants
04/16/15 - 20150104443 - The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with...

Methods related to trastuzumab
04/16/15 - 20150104444 - The present invention relates to the characterization and production of trastuzumab. The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) trastuzumab. In some instances, methods herein allow highly resolved evaluation of trastuzumab useful for, inter alia, manufacturing trastuzumab, characterizing trastuzumab, identifying and/or confirming trastuzumab, monitoring...

Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
04/16/15 - 20150104445 - Methods and compositions are provided for treating diseases implicating alternative pathway complement immune system activation....

Genetic and environmental markers to identify infants at risk for severe lung disease
04/16/15 - 20150104446 - Provided herein are methods and compositions for determining the susceptibility of infants to severe respiratory syncytial virus (RSV) infections. Also provide are methods of treating said subjects prophylactically to reduce the incidence of such infections....

Methods for treating chronic obstructive pulmonary disease using benralizumab
04/16/15 - 20150104447 - Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof....

Anti-complement c1s antibodies and uses thereof
04/16/15 - 20150104448 - The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions....

Variant immunoglobulins with improved manufacturability
04/16/15 - 20150104449 - This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced...

Identification of genetic variants
04/09/15 - 20150098937 - The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or...

Modulators of acyl-coa lysocardiolipin acyltransferase 1 (alcat1) and uses thereof
04/09/15 - 20150098938 - Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided....

Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
04/09/15 - 20150098939 - The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab...

Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
04/09/15 - 20150098940 - The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided....

Anti-glypican-3 antibody
04/09/15 - 20150098941 - An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues....

Methods for inhibiting ocular angiogenesis
04/02/15 - 20150093375 - The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders....

Combination therapy of an afucosylated cd20 antibody with bendamustine
04/02/15 - 20150093376 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine....

Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
04/02/15 - 20150093377 - The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or...

Goodpasture antigen binding protein detection and inhibition and its use in diabetes
04/02/15 - 20150093378 - Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a GPBP inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2...

Novel compositions and methods for treating ige-mediated disorders
04/02/15 - 20150093379 - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma....

Immunopotentiative composition
04/02/15 - 20150093380 - The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment....

Fixed dosing of her antibodies
04/02/15 - 20150093381 - The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab....

Highly concentrated pharmaceutical formulations
03/26/15 - 20150086537 - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of...

Antibody light chains
03/26/15 - 20150086538 - The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid...

Cross-reactive staphylococcus aureus antibody
03/26/15 - 20150086539 - The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as...

Methods of using an antibody to inhibit wnt-mediated cardiac remodeling
03/26/15 - 20150086540 - The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases....

Methods of cytotoxic gene therapy to treat tumors
03/26/15 - 20150086541 - A method is disclosed for decreasing or retarding an increase in the size of a localized or metastatic tumor by using a combination of an immune stimulating cytotoxic gene therapy and immune-checkpoint modulating agent, in conjunction with other therapies, including radiation therapy, chemotherapy, surgery, and immunotherapies....

Compositions and methods for the prevention of microbial infections
03/26/15 - 20150086542 - This disclosure provides methods and compositions to inhibit or prevent infection of a cell by a bacteria that exports DNABII proteins by administering to a tissue infected with the bacteria an effective amount of an antibody that specifically recognizes and binds the DNABII proteins, thereby inhibiting or preventing infection of...

Diagnotic markers
03/26/15 - 20150086543 - The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene....

Stabilized liquid anti-rsv antibody formulations
03/26/15 - 20150086544 - The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof,...

Combination therapy of her expressing tumors
03/26/15 - 20150086545 - The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors....

Humanized anti-ccr2 antibodies and methods of use therefor
03/26/15 - 20150086546 - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of...

Combination therapy for treating breast cancer
03/26/15 - 20150086547 - The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGFβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer....

Non-catalytic domain targets in matrix metalloprotease proteins for cancer therapies
03/19/15 - 20150079071 - The present invention provides compositions and methods for inhibiting MMPs, especially MMP-3, MMP-9 and MMP-14. The invention relates to the field of diagnostic and prognostic methods of human cancers, especially breast cancer and the field of matrix metalloproteases, as targets for diagnostics and therapeutics....

Assays to monitor bleeding disorders
03/19/15 - 20150079072 - The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample...

Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
03/19/15 - 20150079073 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone....

Antibody formulations and methods
03/19/15 - 20150079074 - The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease....

Anti-cd11a antibodies and uses thereof
03/19/15 - 20150079075 - Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection...

Identification of non-responders to her2 inhibitors
03/19/15 - 20150079076 - The present invention relates to means and methods for the identification of non-responders to a HER2 inhibitor, whereby one or more mutations in exon 9 of Phosphoinositol-3 kinase (PIK3CA) indicate non-responsiveness....

Methods and compositions for therapeutic agents
03/19/15 - 20150079077 - The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present...

Biomarkers for triple negative breast cancer
03/19/15 - 20150079078 - The present invention relates to biomarkers that are useful in the prognosis of triple negative breast cancer patients. The biomarkers may be used to select treatment and to determine whether a treatment is effective or not. The biomarkers may also be used to select novel treatments and to screen for...

Methods and compositions for treatment of chlamydial infection and related diseases and disorders
03/19/15 - 20150079079 - The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject....

Novel anti-igf-ir antibodies and uses thereof
03/19/15 - 20150079080 - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic...

Tricyclic p13k inhibitor compounds and methods of use
03/19/15 - 20150079081 - Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described....

Optimized fc variants and methods for their generation
03/19/15 - 20150079082 - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants....

Biomarkers and methods of treating pd-1 and pd-l1 related conditions
03/12/15 - 20150071910 - Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods...

Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
03/12/15 - 20150071911 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus....

Prophylaxis of colorectal and gastrointestinal cancer
03/12/15 - 20150071912 - The present disclosure provides methods and compositions useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, having pre-cancerous adenomatous polyps. The present disclosure provides compositions comprising anti-PG antibodies suitable for use in the methods of the disclosure. The present disclosure also provides methods and compositions useful for monitoring...

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
03/12/15 - 20150071913 - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited...

Methods of treatment using ctla4 mutant molecules
03/12/15 - 20150071914 - The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33...

Monoclonal antibodies against amyloid beta protein and uses thereof
03/12/15 - 20150071915 - The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders....

Anti-cd28 humanized antibodies
03/12/15 - 20150071916 - The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through...

Methods and products for evaluating an immune response to a therapeutic protein
03/12/15 - 20150071917 - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding...

Peptides for the treatment of cancer
03/12/15 - 20150071918 - The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in...

Cancer therapy
03/12/15 - 20150071919 - The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated...

Liquid protein formulations containing water soluble organic dyes
03/12/15 - 20150071920 - Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes....

Liquid protein formulations containing organophosphates
03/12/15 - 20150071921 - Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is...

Liquid protein formulations containing ionic liquids
03/12/15 - 20150071922 - Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids....

Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
03/12/15 - 20150071923 - Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies....

Anti-angiogenesis therapy for the treatment of previously treated breast cancer
03/12/15 - 20150071924 - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer....

Combinations of akt inhibitor compounds and chemotheraeptuc agents, and methods of use
03/05/15 - 20150064171 - The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38,...

Methods of treating a disease or disorder associated with bruton's tyrosine kinase
03/05/15 - 20150064172 - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK....

Methods of treating a disease or disorder associated with bruton's tyrosine kinase
03/05/15 - 20150064173 - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK....

Neutralizing antibody for epstein barr virus-associated disease
03/05/15 - 20150064174 - Described herein are compositions, methods, and uses relating to an EBV-neutralizing antibody....

Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic
03/05/15 - 20150064175 - A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as...

Methods for treating conditions associated with masp-2 dependent complement activation
03/05/15 - 20150064176 - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2...

Therapeutic uses of humanized antibodies against alpha-4 integrin
03/05/15 - 20150064177 - The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated...

Diagnostic methods and compositions for treatment of glioblastoma
03/05/15 - 20150064178 - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods....

Humanized anti-il 10 antibodies for the treatment of systemic lupus erythematosus (sle)
03/05/15 - 20150064179 - Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1L-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving...

Combination therapy with cd4 lymphocyte depletion and mtor inhibitors
03/05/15 - 20150064180 - The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of...